Crystal structure of tert -butyldimethylsilyl-spiroaminooxathioledioxide- thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket

Journal of Medicinal Chemistry

Volumn 54, Issue 8, 2011, Pages 2727-2737

  Das, Kalyan ^a,b   Bauman, Joseph D ^a,b   Rim, Angela S ^a,b   Dharia, Chhaya ^a,b   Clark, Arthur D ^a,b   Camarasa, María José ^c   Balzarini, Jan ^d   Arnold, Eddy ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

[1 [2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 2 N METHYLTHYMINE] 3' SPIRO 5'' (4'' AMINO 1'',2'' OXATHIOLE 2'',2'' DIOXIDE); [2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 3' SPIRO 5'' (4'' AMINO 1'',2'' OXATHIOLE 2'',2'' DIOXIDE)THYMINE; DELAVIRDINE; DIMER; EFAVIRENZ; ETRAVIRINE; GUANOSINE TRIPHOSPHATE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; SPIRO COMPOUND; THYMINE DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION;

CRYSTALLOGRAPHY, X-RAY; ELASTICITY; HIV REVERSE TRANSCRIPTASE; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE;

EID: 79955434216     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101536x     Document Type: Article

References (55)

1. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future Chem. Biodiversity 2004, 1, 44-64
2. Rodgers, D. W.; Gamblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J.; Debouck, C.; Harrison, S. C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1 Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1222-1226
3. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D., Jr.; Hughes, S. H.; Arnold, E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms Structure 1996, 4, 853-860 (Pubitemid 26312368)
4. Bauman, J. D.; Das, K.; Ho, W. C.; Baweja, M.; Himmel, D. M.; Clark, A. D., Jr.; Oren, D. A.; Boyer, P. L.; Hughes, S. H.; Shatkin, A. J.; Arnold, E. Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design Nucleic Acids Res. 2008, 36, 5083-5092
5. Das, K.; Sarafianos, S. G.; Clark, A. D., Jr.; Boyer, P. L.; Hughes, S. H.; Arnold, E. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097 J. Mol. Biol. 2007, 365, 77-89 (Pubitemid 44830031)
6. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Bethune, M.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M.; de Jonge, M. R.; Van Aken, K. J.; Daeyaert, F. F.; Das, K.; Arnold, E.; Janssen, P. A. Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239 (Pubitemid 32781673)
7. Janssen, P. A.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Bethune, M. P.; Pauwels, R.; Das, K.; Clark, A. D., Jr.; Frenkel, Y. V.; Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1 E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine) J. Med. Chem. 2005, 48, 1901-1909 (Pubitemid 40396320)
8. Das, K.; Lewi, P. J.; Hughes, S. H.; Arnold, E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors Prog. Biophys. Mol. Biol. 2005, 88, 209-231 (Pubitemid 39579659)
9. Das, K.; Bauman, J. D.; Clark, A. D., Jr.; Frenkel, Y. V.; Lewi, P. J.; Shatkin, A. J.; Hughes, S. H.; Arnold, E. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1466-1471 (Pubitemid 351346537)
10. Llibre, J. M.; Santos, J. R.; Puig, T.; Molto, J.; Ruiz, L.; Paredes, R.; Clotet, B. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz J. Antimicrob. Chemother. 2008, 62, 909-913
11. Menendez-Arias, L. Molecular basis of human immunodeficiency virus drug resistance: an update Antiviral Res. 2010, 85, 210-231
12. Balzarini, J.; Pérez-Pérez, M. J.; San-Félix, A.; Schols, D.; Perno, C. F.; Vandamme, A. M.; Camarasa, M. J.; De Clercq, E. 2′,5′-Bis- O -(tert -butyldimethylsilyl)-3′-spiro- 5′′-(4′′-amino-1′′,2′′- oxathiole-2′′,2′-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 4392-4396
13. Camarasa, M. J.; San-Félix, A.; Velázquez, S.; Pérez-Pérez, M. J.; Gago, F.; Balzarini, J. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase Curr. Top. Med. Chem. 2004, 4, 945-963 (Pubitemid 38864692)
14. Camarasa, M. J.; Pérez-Pérez, M. J.; San-Félix, A.; Balzarini, J.; De Clercq, E. 3′-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2′-5′-bis- O -(tert -butyldimethylsilyl)-beta- d -xylo- and -ribofuranose]-3′-spiro-5′′-[4′′-amino- 1′′,2′′-oxathiole 2′′,2′′- dioxide] (TSAO) pyrimidine nucleosides J. Med. Chem. 1992, 35, 2721-2727
15. Pérez-Pérez, M. J.; San-Félix, A.; Balzarini, J.; De Clercq, E.; Camarasa, M. J. TSAO-analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis- O -(tert -butyldimethylsilyl)- beta- d -ribofuranosyl]-3′-spiro-5′′-(4′′-amino- 1′′,2′′-oxathiole-2′′,2′′- dioxide) pyrimidine and pyrimidine-modified nucleosides J. Med. Chem. 1992, 35, 2988-2995
16. de Castro, S.; García-Aparicio, C.; Van Laethem, K.; Gago, F.; Lobatón, E.; De Clercq, E.; Balzarini, J.; Camarasa, M. J.; Velázquez, S. Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile Antiviral Res. 2006, 71, 15-23 (Pubitemid 44202207)
17. Camarasa, M. J.; Velázquez, S.; San-Félix, A.; Pérez-Pérez, M. J.; Bonache, M. C.; De Castro, S. TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress Curr. Pharm. Des. 2006, 12, 1895-1907
18. Balzarini, J.; Pérez-Pérez, M. J.; San-Félix, A.; Camarasa, M. J.; Bathurst, I. C.; Barr, P. J.; De Clercq, E. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis- O -(tert -butyldimethylsilyl)-beta- d -ribofuranosyl]-3′-spiro-5′′- (4′′-amino-1′′,2′′-oxathiole- 2′′,2′′-dioxide)thymine (TSAO-T) J. Biol. Chem. 1992, 267, 11831-11838
19. Balzarini, J.; Karlsson, A.; Vandamme, A. M.; Pérez-Pérez, M. J.; Zhang, H.; Vrang, L.; Öberg, B.; Bäckbro, K.; Unge, T.; San-Félix, A.; Velázquez, S.; Camarasa, M. J.; De Clercq, E. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis- O -(tert -butyldimethylsilyl)- 3′-spiro-5′′-(4′′-amino-1′′, 2′′-oxathiole-2′′,2′′-dioxide)]-beta- d -pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6952-6956 (Pubitemid 23222366)
20. Balzarini, J.; Karlsson, A.; Pérez-Pérez, M. J.; Vrang, L.; Walbers, J.; Zhang, H.; Öberg, B.; Vandamme, A. M.; Camarasa, M. J.; De Clercq, E. HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase Virology 1993, 192, 246-253
21. Balzarini, J.; Karlsson, A.; Pérez-Pérez, M. J.; Camarasa, M. J.; De Clercq, E. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus Virology 1993, 196, 576-585
22. Paris, K. A.; Haq, O.; Felts, A. K.; Das, K.; Arnold, E.; Levy, R. M. Conformational landscape of the human immunodeficiency virus type 1 reverse transcriptase non-nucleoside inhibitor binding pocket: lessons for inhibitor design from a cluster analysis of many crystal structures J. Med. Chem. 2009, 52, 6413-6420
23. Sluis-Cremer, N.; Dmitrienko, G. I.; Balzarini, J.; Camarasa, M. J.; Parniak, M. A. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro[4′′-amino-2′′, 2′′-dioxo-1′′,2′′-oxathiole-5′′, 3′-[2′, 5′-bis- O -(tert -butyldimethylsilyl)-beta- d -ribofuranosyl]]]-3-ethylthymine Biochemistry 2000, 39, 1427-1433 (Pubitemid 30090712)
24. Sluis-Cremer, N.; Hamamouch, N.; San Felix, A.; Velázquez, S.; Balzarini, J.; Camarasa, M. J. Structure-activity relationships of [2′,5′-bis- O -(tert -butyldimethylsilyl)-beta- d -ribofuranosyl]-3′-spiro-5′′-(4′′-amino- 1′′,2′′-oxathiole-2′′,2′′- dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization J. Med. Chem. 2006, 49, 4834-4841 (Pubitemid 44202171)
25. Tachedjian, G.; Orlova, M.; Sarafianos, S. G.; Arnold, E.; Goff, S. P. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 7188-7193 (Pubitemid 32567924)
26. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors Nature Struct. Biol. 1995, 2, 407-415
27. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors J. Med. Chem. 1996, 39, 1589-1600
28. Himmel, D. M.; Das, K.; Clark, A. D., Jr.; Hughes, S. H.; Benjahad, A.; Oumouch, S.; Guillemont, J.; Coupa, S.; Poncelet, A.; Csoka, I.; Meyer, C.; Andries, K.; Nguyen, C. H.; Grierson, D. S.; Arnold, E. Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains J. Med. Chem. 2005, 48, 7582-7591 (Pubitemid 41698799)
29. Ingate, S.; Pérez-Pérez, M. J.; De Clercq, E.; Balzarini, J.; Camarasa, M. J. Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2′- and 5′-positions of the sugar moiety Antiviral Res. 1995, 27, 281-299
30. Chamorro, C.; Pérez-Pérez, M. J.; Rodríguez-Barrios, F.; Gago, F.; De Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M. J. Exploiting the role of the 5′-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives Antiviral Res. 2001, 50, 207-222 (Pubitemid 32536710)
31. San-Félix, A.; Chamorro, C.; Pérez-Pérez, M. J.; Velázquez, S.; De Clercq, E.; Balzarini, J.; Camarasa, M. J. Synthesis of novel 5′-substituted TSAO-T analogues with anti-HIV-1 activity J. Carbohydr. Chem. 2000, 19, 635-640
32. Das, K.; Clark, J., A.D.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; de Béthune, M.-P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A. J.; Arnold, E. Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants J. Med. Chem. 2004, 47, 2550-2560 (Pubitemid 38580092)
33. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D., Jr.; Boyer, P. L.; Lewi, P.; Janssen, P. A.; Kleim, J. P.; Rosner, M.; Hughes, S. H.; Arnold, E. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance J. Mol. Biol. 2001, 309, 437-445 (Pubitemid 32564904)
34. Ren, J.; Milton, J.; Weaver, K. L.; Short, S. A.; Stuart, D. I.; Stammers, D. K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase Structure 2000, 8, 1089-1094 (Pubitemid 32667472)
35. Lindberg, J.; Sigurdsson, S.; Löwgren, S.; Andersson, H. O.; Sahlberg, C.; Noréen, R.; Fridborg, K.; Zhang, H.; Unge, T. Eur. J. Biochem. 2002, 269, 1670-1677
36. Udier-Blagovic̀, M.; Tirado-Rives, J.; Jorgensen, W. L. Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues J. Med. Chem. 2004, 47, 2389-2392 (Pubitemid 38478862)
37. Balzarini, J.; Karlsson, A.; Pérez-Pérez, M. J.; Camarasa, M. J.; Tarpley, W. G.; De Clercq, E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy J. Virol. 1993, 67, 5353-5359 (Pubitemid 23241368)
38. Boyer, P. L.; Ding, J.; Arnold, E.; Hughes, S. H. Subunit specificity of mutations that confer resistance to non-nucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother. 1994, 38, 1909-1914 (Pubitemid 24278778)
39. Pelemans, H.; Aertsen, A.; Van Laethem, K.; Vandamme, A. M.; De Clercq, E.; Pérez-Pérez, M. J.; San-Félix, A.; Velázquez, S.; Camarasa, M. J.; Balzarini, J. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138 Virology 2001, 280, 97-106 (Pubitemid 34162519)
40. Ren, J.; Nichols, C. E.; Stamp, A.; Chamberlain, P. P.; Ferris, R.; Weaver, K. L.; Short, S. A.; Stammers, D. K. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138 FEBS J. 2006, 273, 3850-3860 (Pubitemid 44172616)
41. Rodríguez-Barrios, F.; Pérez, C.; Lobatón, E.; Velázquez, S.; Chamorro, C.; San-Félix, A.; Pérez- Pérez, M. J.; Camarasa, M. J.; Pelemans, H.; Balzarini, J.; Gago, F. Identification of a putative binding site for [2′,5′-bis- O -(tert -butyldimethylsilyl)-beta- d -ribofuranosyl]-3′-spiro-5′′- (4′′-amino-1′′,2′′-oxathiole- 2′′,2′′-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase J. Med. Chem. 2001, 44, 1853-1865 (Pubitemid 32888185)
42. Balzarini, J.; Auwerx, J.; Rodríguez-Barrios, F.; Chedad, A.; Farkas, V.; Ceccherini-Silberstein, F.; García-Aparicio, C.; Velázquez, S.; De Clercq, E.; Perno, C. F.; Camarasa, M. J.; Gago, F. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors Mol. Pharmacol. 2005, 68, 49-60 (Pubitemid 41007052)
43. Upadhyay, A.; Pandey, N.; Mishra, C. A.; Talele, T. T.; Pandey, V. N. A single deletion at position 134, 135, or 136 in the beta 7-beta 8 loop of the p51 subunit of HIV-1 RT disrupts the formation of heterodimeric enzyme J. Cell. Biochem. 2010, 109, 598-605
44. Bonache, M. C.; Chamorro, C.; Velázquez, S.; De Clercq, E.; Balzarini, J.; Barrios, F. R.; Gago, F.; Camarasa, M. J.; San-Félix, A. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position J. Med. Chem. 2005, 48, 6653-6660 (Pubitemid 41509181)
45. Velázquez, S.; San-Félix, A.; Pérez-Pérez, M. J.; Balzarini, J.; De Clercq, E.; Camarasa, M. J. TSAO analogues. 3. Synthesis and anti-HIV-1 activity of 2′,5′-bis- O -(tert -butyldimethylsilyl)- beta- d -ribofuranosyl 3′-spiro-5′′-(4′′-amino- 1′′,2′′-oxathiole 2′′,2′′- dioxide) purine and purine-modified nucleosides J. Med. Chem. 1993, 36, 3230-3239 (Pubitemid 23335686)
46. Alvarez, R.; Velázquez, S.; San-Félix, A.; Aquaro, S.; De Clercq, E.; Perno, C. F.; Karlsson, A.; Balzarini, J.; Camarasa, M. J. 1,2,3-Triazole-[2′,5′-bis- O -(tert -butyldimethylsilyl)-beta- d -ribofuranosyl]-3′-spiro-5′′-(4′′-amino- 1′′,2′′-oxathiole 2′′,2′′- dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity J. Med. Chem. 1994, 37, 4185-4194
47. Alvarez, R.; Jimeno, M. L.; Pérez-Pérez, M. J.; De Clercq, E.; Balzarini, J.; Camarasa, M. J. Synthesis and anti-human immunodeficiency virus type 1 activity of novel 3′-spiro nucleoside analogues of TSAO-T Antivir. Chem. Chemother. 1997, 8, 507-517 (Pubitemid 27504715)
48. Alvarez, R.; Jimeno, M. L.; Gago, F.; Balzarini, J.; Pérez- Pérez, M. J.; Camarasa, M. J. Novel 3′-spiro nucleoside analogues of TSAO-T. Part II. A comparative study based on NMR conformational analysis in solution and theoretical calculations Antiviral Chem. Chemother. 1998, 9, 333-340 (Pubitemid 28368255)
49. de Castro, S.; Lobatón, E.; Pérez-Pérez, M. J.; San-Félix, A.; Cordeiro, A.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J.; Camarasa, M. J.; Velázquez, S. Novel [2′,5′- bis- O -(tert -butyldimethylsilyl)-beta- d -ribofuranosyl]-3′-spiro- 5′′-(4′′-amino-1′′,2′′- oxathiole-2′′,2′′-dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity J. Med. Chem. 2005, 48, 1158-1168 (Pubitemid 40270458)
50. Otwinowski, Z.; Minor, W. DENZO and SCALEPACK. In Crystallography of Biological Macromolecules; Rossmann, M. G.; Arnold, E., Eds.; Kluwer Academic Publishers: Boston, 2001; Vol. F, pp 226 - 235.
51. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132 (Pubitemid 41742764)
52. Brunger, A. T. Version 1.2 of the Crystallography and NMR system Nature Protoc. 2007, 2, 2728-2733
53. Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 213-221
54. Laskowski, R. A.; MacArthur, M. W.; Thornton, J. M. Evaluation of protein coordinate data sets, in From First Map to Final Model. In Proceedings of the CCP4 Study Weekend; Bailey, S.; Hubbard, R.; Waller, D., Eds.; Daresbury Laboratory: Warrington, UK, 1994; pp 149 - 159.
55. Bonache, M. C.; Quesada, E.; Sheen, C. W.; Balzarini, J.; Sluis-Cremer, N.; Pérez-Pérez, M. J.; Camarasa, M. J.; San-Félix, A. Novel N-3 substituted TSAO-T derivatives: synthesis and anti-HIV-evaluation Nucleosides, Nucleotides Nucleic Acids 2008, 27, 351-367 (Pubitemid 351521135)